[1] |
Agoritsas T, Merglen A, Shah ND, et al. Adjusted analyses in studies addressing therapy and harm: Users' guides to the medical literature. JAMA, 2017; 317, 748−59. doi: 10.1001/jama.2016.20029 |
[2] |
Duggan JP, Peters AS, Trachiotis GD, et al. Epidemiology of coronary artery disease. Surg Clin North Am, 2022; 102, 499−516. doi: 10.1016/j.suc.2022.01.007 |
[3] |
Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet, 2010; 376, 1670−81. doi: 10.1016/S0140-6736(10)61350-5 |
[4] |
Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet, 2005; 366, 1267−78. doi: 10.1016/S0140-6736(05)67394-1 |
[5] |
Alieva AS, Tokgözoğlu L, Ray KK, et al. Lipid clinics network. Rationale and design of the EAS global project. Atheroscler Suppl, 2020; 42, e6−8. doi: 10.1016/j.atherosclerosissup.2021.01.002 |
[6] |
Parikh PB, Bhatt DL, Bhasin V, et al. Impact of percutaneous coronary intervention on outcomes in patients with Heart Failure: JACC State-of-the-art review. J Am Coll Cardiol, 2021; 77, 2432−47. |
[7] |
Cho KH, Jeong MH, Ahn Y, et al. Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox). Am J Cardiol, 2010; 106, 1061−8. doi: 10.1016/j.amjcard.2010.06.009 |
[8] |
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2017; 38, 2459−72. doi: 10.1093/eurheartj/ehx144 |
[9] |
Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol, 2012; 60, 2631−9. doi: 10.1016/j.jacc.2012.09.017 |
[10] |
Amarenco P, Hobeanu C, Labreuche J, et al. Carotid atherosclerosis evolution when targeting a low-density lipoprotein cholesterol concentration <70 mg/dL after an ischemic stroke of atherosclerotic origin. Circulation, 2020; 142, 748−57. doi: 10.1161/CIRCULATIONAHA.120.046774 |
[11] |
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J, 2021; 42, 3227−337. doi: 10.1093/eurheartj/ehab484 |
[12] |
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation, 2019; 139, e1082−143. |
[13] |
Joint committee issued Chinese guideline for the management of dyslipidemia in adults. 2016 Chinese guideline for the management of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi, 2016; 44, 833−53. (In Chinese) |
[14] |
Shin S, Park HB, Chang HJ, et al. Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT angiography study. JACC Cardiovasc Imaging, 2017; 10, 437−46. doi: 10.1016/j.jcmg.2016.04.013 |
[15] |
Lamb YN. Rosuvastatin/ezetimibe: a review in hypercholesterolemi. Am J Cardiovasc Drugs, 2020; 20, 381−92. doi: 10.1007/s40256-020-00421-1 |
[16] |
Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT Trial. Circulation, 2018; 138, 770−781. doi: 10.1161/CIRCULATIONAHA.117.032318 |
[17] |
Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation, 2010; 121, 948−54. doi: 10.1161/CIRCULATIONAHA.109.192666 |
[18] |
Xiang AS, Kingwell BA. Rethinking good cholesterol: a clinicians' guide to understanding HDL. Lancet Diabetes Endocrinol, 2019; 7, 575−82. doi: 10.1016/S2213-8587(19)30003-8 |
[19] |
Reddy VS, Bui QT, Jacobs JR, et al. Relationship between serum low-density lipoprotein cholesterol and in-hospital mortality following acute myocardial infarction (the lipid paradox). Am J Cardiol, 2015; 115, 557−62. doi: 10.1016/j.amjcard.2014.12.006 |
[20] |
Nunes JPL. Statins and the cholesterol mortality paradox. Scott Med J, 2017; 62, 19−23. doi: 10.1177/0036933016681913 |
[21] |
Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J, 2014; 35, 2950−9. doi: 10.1093/eurheartj/ehu299 |
[22] |
Wang TY, Newby LK, Chen AY, et al. Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. Clin Cardiol, 2009; 32, E22−8. |
[23] |
Sun HN, Li ZP, Song XW, et al. Revisiting the lipid paradox in ST-elevation myocardial infarction in the Chinese population: findings from the CCC-ACS project. Eur Heart J Acute Cardiovasc Care, 2021; 10, 978−87. doi: 10.1093/ehjacc/zuab053 |
[24] |
Wang B, Liu J, Chen SQ, et al. Malnutrition affects cholesterol paradox in coronary artery disease: a 41, 229 Chinese cohort study. Lipids Health Dis, 2021; 20, 36. doi: 10.1186/s12944-021-01460-6 |
[25] |
Outland B, Newman MM, William MJ. Health policy basics: implementation of the international classification of disease, 10th revision. Ann Intern Med, 2015; 163, 554−6. doi: 10.7326/M15-1933 |
[26] |
Strandberg TE, Pyörälä K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet, 2004; 364, 771−7. doi: 10.1016/S0140-6736(04)16936-5 |
[27] |
Akyea RK, Vinogradova Y, Qureshi N, et al. Sex, Age, and socioeconomic differences in nonfatal stroke incidence and subsequent major adverse outcomes. Stroke, 2021; 52, 396−405. doi: 10.1161/STROKEAHA.120.031659 |
[28] |
Kanonidou C. Small dense low-density lipoprotein: analytical review. Clin Chim Acta, 2021; 520, 172−8. doi: 10.1016/j.cca.2021.06.012 |
[29] |
Shiffman D, Louie JZ, Caulfield MP, et al. LDL subfractions are associated with incident cardiovascular disease in the Malmö Prevention Project Study. Atherosclerosis, 2017; 263, 287−92. doi: 10.1016/j.atherosclerosis.2017.07.003 |
[30] |
Bajer B, Rádiková Ž, Havranová A, et al. Effect of 8-weeks intensive lifestyle intervention on LDL and HDL subfractions. Obes Res Clin Pract, 2019; 13, 586−93. doi: 10.1016/j.orcp.2019.10.010 |
[31] |
Gorog DA, Yamamoto J, Saraf S, et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the "Japanese paradox". Int J Cardiol, 2011; 152, 43−8. doi: 10.1016/j.ijcard.2010.07.002 |
[32] |
Expert Panel on Dyslipidemia. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol, 2013; 7, 561−5. doi: 10.1016/j.jacl.2013.10.001 |
[33] |
Rong, Shuang et al. Association of low-density lipoprotein cholesterol levels with more than 20-Year risk of cardiovascular and all-cause mortality in the general population. J Am Heart Assoc, 2022; 11, e023690. doi: 10.1161/JAHA.121.023690 |
[34] |
Yang Q, Sun DD, Pei CZ et al. LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project. Eur Heart J, 2021; 42, 3175−86. doi: 10.1093/eurheartj/ehab418 |
[35] |
Zakai NA, McClure LA. Racial differences in venous thromboembolism. J Thromb Haemost, 2011; 9, 1877−82. doi: 10.1111/j.1538-7836.2011.04443.x |
[36] |
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease-Executive Summary. Endocr Pract, 2017; 23, 479−97. doi: 10.4158/EP171764.GL |